Immunotherapy in Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis: From Poor Prognosis to Curative-Intent Strategies
The combination of multiple therapies could improve the patient's prognosis by achieving objective response rate of almost 82%, disease control rate of 97% and progression free survival of 12.9 months with quadruple therapy (HAIC-TACE combined with targeted and immunotherapy).
Authors
- Luisa Siciliani (ORCID: https://orcid.org/0000-0003-3386-6014)
- Luca Marzi (ORCID: https://orcid.org/0000-0003-1464-9700)
- Rodolfo Sacco
- Mauro Giuffrè (ORCID: https://orcid.org/0000-0002-9910-3514)
- Cristina Stasi (ORCID: https://orcid.org/0000-0002-9146-9968)
- Saveria Lory Crocé
- C Turri
- Monica Zoeschg
- Andrea Mega on behalf of the A.I.G.O. (Italian Association of Hospital Mega
Institutions
- University of Foggia (IT)
- University of Trieste (IT)
- Ospedale di Bolzano (IT)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Azienda Sanitaria Universitaria Integrata di Trieste (IT)
- Link Campus University (IT)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-14
- DOI
- https://doi.org/10.3390/cancers18040627
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00